Trius Therapeutics Chops IPO Offering Price

San Diego-based Trius Therapautics has slashed its IPO offering price, saying today in a filing with the SEC that it will offer 10,000,000 shares of its common stock at $5.00 per share. The firm, which will list on the Nasdaq Global Market as TSRX, had initially said it would sell 6,000,000 shares of its stock at between $12.00 and $14.00 per share. Trius is a developer of antibiotics, and is venture backed by Sofinnova Venture Partners, InterWest Partners, Versant Ventures, Prism Venture Partners, and Kleiner Perkins Caufield & Byers. The firm's IPO is being underwritten by Citi, Piper Jaffray, Canaccord Genuity, and JMP Securities.